BioSpace News Archive

Vector BioPharma AG announced that it has entered into a strategic, multi-phase collaboration with the Instituto de Biologia Experimental e Tecnológica, a world-leading research-intensive organization specialized in biotechnology research and bioprocess development.

KRONOS ADVANCED TECHNOLOGIES, INC. announced today that the U.S. Food and Drug Administration (FDA) has recently granted 510(k) clearance, classifying it as a Class II Medical Device.

QSAM Biosciences Inc. provides the following update to shareholders regarding progress made in 2022 and milestone goals for 2023.

Bio-Techne Corporation (NASDAQ: TECH) today announced the expansion of its Advanced Cell Diagnostics (ACD)-branded RNAscope™ in situ hybridization (ISH) portfolio with the release of the RNAscope Plus smRNA-RNA detection assay.

Calibre Scientific is pleased to announce the acquisition of Dynalab Corp., a Rochester, NY based distributor and manufacturer of laboratory plastics, consumables, equipment, supplies and custom fabricated products serving the scientific, industrial, agricultural, water, pharma and educational markets in the United States.

cultivate Capital Funds LP, funds that are focused on investments into early-stage healthcare companies with innovative technologies, announced that one of their portfolio companies, Norfolk, VA-based Embody, Inc., a privately held medical device company focused on soft tissue healing, has reached an agreement with Zimmer Biomet Holdings, Inc., a global leader in medical technology, to be acquired.

EndoTheia Inc.announced today that it has gained priority status from the FDA by receiving a Breakthrough Device designation from the agency for its technology that radically improves minimally invasive flexible endoscopic surgery.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced the addition of Neurology Center of New England, P.C. to its Therapeutic Experience Program.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that BCLI will donate biospecimens from NurOwn’s placebo-controlled Phase 3 ALS trial to the Northeast Amyotrophic Lateral Sclerosis Consortium (NEALS) biorepository for use by the research community.

Kymera Therapeutics, Inc. today announced its research, development and corporate goals for 2023.